Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis

Journal of Clinical Pharmacology

Volumn 46, Issue 11, 2006, Pages 1259-1267

  Teigen, Mette Maja B ^a   Duffull, Stephen ^a,b,c   Dang, Lily ^a   Johnson, David W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Aminoglycosides; End stage renal disease; Hemodialysis; Pharmacokinetics

Indexed keywords

CREATININE; GENTAMICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; COCKCROFT AND GAULT EQUATION; CREATININE CLEARANCE; DATA ANALYSIS SOFTWARE; DEVICE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; EVALUATION; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE; MATHEMATICAL ANALYSIS; OUTCOME ASSESSMENT; POPULATION MODEL; PROBABILITY; SIMULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENTAMICINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33749868047     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006292987     Document Type: Article

References (31)

1. Goodkin DA, Mapes DL, Held PJ. The dialysis outcomes and practice patterns study (DOPPS): how can we improve the care of hemodialysis patients? Sem Dialysis. 2001;14:157-159.
2. McDonald SP, Russ GR, Kerr PG, Collins JF. ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. Am J Kidney Dis. 2002;40:1122-1131.
3. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000;58:1758-1764.
4. Matsuo H, Hayashi J, Ono K, et al. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality. Antimicrob Agents Chemother. 1997;41: 2597-2601.
5. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984;149:443-448.
6. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984;77:657-662.
7. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
8. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831-847.
9. Barclay ML, Begg EJ. Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs. 2001;61:713-721.
10. Barclay ML, Begg EJ, Chambers ST. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother. 1992;36:1951-1957.
11. Barclay ML, Begg EJ, Chambers ST, Peddie BA. The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro. J Antimicrob Chemother. 1996;38:853-858.
12. Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother. 1996;37:1155-1164.
13. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984;149:23-30.
14. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100:352-357.
15. Giuliano RA, Verpooten GA, Verbist L, Wedeen RP, De Broe ME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther. 1986;236:470-475.
16. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989;45:22-27.
17. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605-609.
18. Barclay ML, Duffull SB, Begg EJ, Buttimore RC. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust NZ J Med. 1995;25:230-235.
19. Dang L, Duffull S. Development of a semi-mechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis. J Clin Pharmacol. 2006;46:662-673.
20. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis. 2005;46:681-687.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
22. Pesola GR, Akhavan I, Madu A, Shah NK, Carlon GC. Prediction equation estimates of creatinine clearance in the intensive care unit. Intensive Care Med. 1993;19:39-43.
23. Devine D. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-655.
24. Bauer JH, Brooks CS, Burch RN. Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate. Am J Kidney Dis. 1982;2:337-346.
25. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830-838.
26. Milutinovic J, Cutler RE, Hoover P, Meijsen B, Scribner BH. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis [abstract]. Kidney Int. 1975;8:185-190.
27. Luke DR, Halstenson CE, Opsahl JA, Matzke GR. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther. 1990;48:503-508.
28. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol. 1999;47:637-643.
29. Amin NB, Padhi ID, Touchette MA, Patel RV, Dunfee TP, Anandan JV. Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. Am J Kidney Dis. 1999;34:222-227.
30. Vercaigne LM, Ariano RE, Zacharias JM. Bayesian pharmacokinetics of gentainicin in a haemodialysis population. Clin Pharmacokinet. 2004;43:205-210.
31. Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents. 2004;23:291-295.